OncoMatch/Clinical Trials/NCT05440227
PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
Is NCT05440227 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PG2 Lyo. for cancer-related fatigue.
Treatment: PG2 Lyo. — The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
hgb ≥ 10 g/dl (patients must not be transfused ≤ 14 days to meet this criterion)
Kidney function
creatinine ≤ 1.2 x uln
Liver function
ast (sgot) or alt (sgpt) ≤1.5 x uln (or ≤5.0 x uln for patients with liver metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify